Answers are grounded in this paper and cite their sources.
Fibroblast growth factor 21 (FGF21) is a key regulator in metabolic diseases. Serum FGF21 levels are significantly elevated in patients with hyperuricemia and correlate positively with uric acid. In hyperuricemic mice, FGF21 is selectively upregulated in white adipose tissue but not in the liver, independent of the integrated stress response. Adipose-specific or global FGF21 knockout exacerbated hyperuricemia, increased hepatic xanthine oxidase (XOD) activity, and aggravated aortic endothelial dysfunction, oxidative stress, iNOS/eNOS imbalance, and hepatic lipid accumulation. These alterations were reversed by exogenous FGF21 supplementation. Mechanistically, FGF21 promotes AMPK phosphorylation and upregulates glutathione S-transferase P1 (GSTP1). GSTP1 depletion abolished FGF21-mediated uric acid reduction, XOD suppression, oxidative stress alleviation, and endothelial protection, indicating that GSTP1 is essential for FGF21’s protective effects. Collectively, these findings reveal an FGF21–AMPK–GSTP1 regulatory axis that suppresses hepatic urate production, ameliorates hyperuricemia, and alleviates aortic endothelial injury and hepatic steatosis. This axis represents a potential therapeutic target for hyperuricemia and its associated cardiovascular and metabolic complications.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: